Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Autologous genetically modified AFPᶜ³³²T cells · 1 trial · 2 indications
Determine if treatment with autologous genetically modified T cells, (AFPᶜ³³²T) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments including chemistry, hematology, coagulation, cardiac assessments including ECG, and cardiac Troponin
| Arm | Type | Description |
|---|---|---|
| Autologous genetically modified AFPᶜ³³²T cells | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Autologous genetically modified AFPᶜ³³²T cells | GENETIC | Infusion of autologous genetically modified AFPᶜ³³²T cells |
Key Inclusion Criteria: 1. Subject is ≥ 18 years and ≤ 75 years of age and has voluntarily agreed to participate by giving written informed consent in accordance with ICH GCP Guidelines and applicable local regulations. 2. Histologically confirmed HCC, not amenable to transplant, resection. Subject...
Autologous genetically modified AFPc332T cells is an investigational gene therapy being developed for hepatocellular cancer, a type of liver cancer. It is designed to target tumors that express alpha-fetoprotein (AFP). The therapy is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Autologous genetically modified AFPc332T cells targets alpha-fetoprotein (AFP), a protein expressed on the surface of certain tumor cells. The therapy involves genetically modifying a patient's own T cells to recognize and attack AFP-expressing cancer cells, potentially offering a targeted approach to treating hepatocellular cancer.
Autologous genetically modified AFPc332T cells is being developed by Adaptimmune Therapeutics PLC, a biopharmaceutical company. The company's sponsored ADR trades under the ticker symbol ADAP on the NASDAQ stock exchange.
Autologous genetically modified AFPc332T cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not yet been approved by the FDA or other regulatory agencies. The therapy is being studied in a single active clinical trial for hepatocellular cancer.
Autologous genetically modified AFPc332T cells is being studied in one active clinical trial, identified as NCT03132792, titled 'AFPc332T in Advanced HCC'. This Phase 1 trial is enrolling 45 participants with hepatocellular cancer or AFP-expressing tumors across the United States, France, Spain, and the United Kingdom.
Yes, Autologous genetically modified AFPc332T cells is the same as AFPc332T. The full name describes the autologous, genetically modified nature of the cells, while AFPc332T is the abbreviated name used in clinical trial documentation and scientific literature.